ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.
Christopher T ChenVishesh KhannaShivaani KummarRaghad M Abdul-KarimDavid SommerhalderAnthony W TolcherNaoto Tada UenoS Lindsey DavisDouglas W OrrErika Paige HamiltonManish R PatelAlexander I SpiraShekeab JauhariVaia FlorouMaureen DuffRongda XuJian WangShravani R BarkundHaiying ZhouAleksandr PankovWayne KongNadine S JahchanErica L JacksonJessica D SunMelissa R JunttilaPratik S MultaniAnneleen DaemenEdna Chow-ManevalPamela N MunsterPublished in: Cancer research communications (2024)
ORIC-101 with nab-paclitaxel showed limited clinical activity in taxane-resistant solid tumors. Despite clear inhibition of GR pathway signaling, the insufficient clinical signal underscores the challenges of targeting a single resistance pathway when multiple mechanisms of resistance may be in play.
Keyphrases